Bernstein Says Novartis Should Explain Pipeline’s Role in 2030s Growth

Bernstein analysts say Novartis may need to explain at an investor event next month which pipeline drugs could drive sales growth in the 2030s. The company expects top-line growth in the mid-single-digit percentage range during that decade.